Investigating how THC and CBD affect inflammation and immune function in HIV infection
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection
This study is looking at how THC and CBD, two important parts of cannabis, might help reduce inflammation and improve immune function in people living with HIV, making it easier for their bodies to fight off infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10888346 on NIH RePORTER |
What this research studies
This research explores the effects of THC and CBD, two major components of cannabis, on inflammation and immune dysfunction associated with HIV infection. The study focuses on understanding how these compounds can influence immune cell activation and inflammation in the central nervous system, which is crucial for patients living with HIV. By examining the mechanisms through which THC and CBD interact with cannabinoid receptors, the research aims to identify potential therapeutic benefits for reducing chronic inflammation and improving immune responses in HIV-positive individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who experience chronic immune activation and inflammation.
Not a fit: Patients who are not living with HIV or those who do not experience chronic inflammation related to their condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that alleviate chronic inflammation and improve immune function in HIV patients.
How similar studies have performed: Previous studies have shown promising results regarding the anti-inflammatory properties of THC and CBD, suggesting potential benefits in similar contexts, although this specific approach is relatively novel.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zhen, Anjie — University of California Los Angeles
- Study coordinator: Zhen, Anjie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.